select a format

Single User License
USD 250 INR 16018
Site License
USD 500 INR 32035
Corporate User License
USD 750 INR 48053

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Merck KGaA (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Merck KGaA (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH48505D
  • |
  • Pages: 264
  • |
  • November 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Merck KGaA (Merck) is a pharmaceutical and chemical company, which operates its business in three markets namely, healthcare market, performance materials market and life sciences market. Its business operations include promoting prescription drugs of chemical and biological origin and over-the-counter products for preventive health care and the self-treatment of minor ailments (healthcare market); identifying, developing and manufacturing biotech and pharmaceutical drugs and general laboratory applications (life sciences market); and developing liquid crystal mixtures and cosmetic active ingredients (performance materials market). The company has operations in over 66 countries spread across Europe, North America, South America, Africa, Asia and Australia. It is a subsidiary of E. Merck KG and is headquartered in Darmstadt, Germany.

Merck KGaA (MRK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 12

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 13

Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 15

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 16

Merck KGaA, Medical Devices Deals, 2010 to YTD 2016 18

Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 19

Merck KGaA, Pharmaceuticals & Healthcare, Deal Details 31

Asset Purchase 31

Merck KgaA Acquires SevenSeas Original Brand 31

Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 32

Venture Financing 33

Asceneuron Raises USD30.6 Million in Series A Financing 33

TocopheRx Raises US$3.3 Million In Seed Financing 35

Asceneuron Raises US$6.4 Million In Seed Financing 36

VAXIMM Secures US$8 Million In Venture Financing 37

Private Equity 39

Merck Sells Its Pharma Operations To Nkunzi Investment And Omame 39

Partnerships 40

Proteome Sciences Enters Into License Agreement With Sigma-Aldrich 40

BioMed X Enters into Agreement with Merck 41

Debiopharm Partners with Merck and Pfizer 42

Transgene Enters into Agreement with Merck and Pfizer 43

Vaccinex Enters into Agreement with Merck 44

PCAS Enters into Distribution Agreement with MilliporeSigma 45

MilliporeSigma Enters into Research Agreement with International Vaccine Institute 46

Selvita Enters into Agreement with Merck 47

Merck Enters into Agreement with University of Buea 48

Merck, Pfizer and Verastem Enter into Agreement 49

Merck Enters into Research Agreement with European Molecular Biology Labs 50

Merck, Pfizer and Syndax Pharma Enter into Agreement 51

Selvita Enters into Development and Commercialization Agreement with Merck 52

Biothera Pharma Enters into Partnership with Merck 53

Sigma-Aldrich Enters into Agreement with Sanger Institute 54

Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 55

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 56

Aeterna Zentaris Enters into Agreement with EMD Serono 57

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 58

Lucigen Enters into Distribution Agreement with Sigma-Aldrich 59

Merck Serono Enters into Co-Development Agreement with MMV 60

Sigma-Aldrich Enters into Distribution Agreement with Roche 61

Merck Enters into Development Agreement with Precision Biologics 62

Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 63

Pfizer Enters into Co-Development Agreement with Merck 64

BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 66

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 67

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 68

Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 69

Lupin Enters into Co-Development Agreement with Merck Serono 70

Merck Serono Extends R&D Agreement with San Raffaele 71

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 72

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 73

Bionovis Enters into Agreement with Merck 74

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 75

EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 77

KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 78

Biopharm Enters Into Research Agreement With Merck Serono 79

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 80

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 81

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 82

Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 83

Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 85

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 86

Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 88

Isu Abxis Enters into Co-Development Agreement with Merck 89

Luminex Extends Distribution Agreement With EMD Millipore 90

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 91

Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 92

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 93

Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 94

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 96

EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 97

AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 98

EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 99

Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 100

Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 101

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 102

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 103

Genovis Enters Into Distribution Agreement With Sigma-Aldrich 104

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 105

EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 106

EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 107

Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 108

Mapi Pharma Amends Co-Development Agreement with Merck 110

TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 111

Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 112

IntelliCell BioSciences Enters Into Co-Marketing Agreement With Millipore 113

f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 114

BASF Enters Into Distribution Agreement With Sigma-Aldrich 115

Lead Discovery Center Enters Into Agreement With Merck Serono 116

Merck Serono Enters Into Research Agreement With Philochem 117

Merck Serono Enters Into Co-Development Agreement With Sanofi-aventis 118

EMD Serono Enters Into Co-Marketing Agreement With Tercica 119

Merck Serono Extends Co-Development Agreement With INSpe And Department Of Neurology Of San Raffaele 120

Evotec Enters Into Collaboration With Merck KGaA 121

Domainex Enters Into Collaboration With Sigma-Aldrich 122

Sigma Life Science Enters Into Co-Marketing Agreement With JAX 123

Sigma Life Science Enters Into An Agreement With Autism Speaks 124

Ablynx Enters Into Second Co-Discovery And Co-Development Agreement With Merck Serono 125

EDELRIS Enters Into Collaboration With Merck Serono 126

Generex Biotech Enters Into Co-Marketing Agreement With Merck 127

Sigma Life Science Enters Into An Agreement With SwitchGear 128

Millipore Enters Into Collaboration With BioOutsource 129

Sigma-Aldrich Enters Into Distribution Agreement With New Mexico Highlands 130

Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim 131

Swedish Orphan Biovitrum Expands Distribution Agreement With Merck Serono 132

Eden Biodesign Enters Into A Collaboration With Millipore 133

Sigma-Aldrich Enters Into Commercialization Agreement With Pfizer 134

Sigma-Aldrich Enters Into Distribution Agreement With Eka Chemicals 135

BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono 136

Cancer Research And Cancer Research Technology Enter Into An Agreement With Merck 137

Licensing Agreements 138

Merck Enters into Licensing Agreement with Weizmann Institute of Science 138

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 139

EMD Millipore Enters into Licensing Agreement with Singulex 140

Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 141

Intrexon Enters into Licensing Agreement with Merck Serono 142

Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 143

EMD Serono Enters into Licensing Agreement with Sutro Biopharma 144

Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 146

EMD Serono Enters into Licensing Agreement with Mersana Therapeutics 148

MorphoSys Enters into Licensing Agreement with Merck Serono 149

Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 150

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 152

Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 153

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 154

ObsEva Enters Into Licensing Agreement With Merck Serono 155

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 156

Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 158

Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 160

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 161

Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 162

Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 163

Merck Serono Amends Option and Licensing Agreement with Opexa Therapeutics 164

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 166

EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 167

Materia Extends Licensing Agreement With Sigma Aldrich 168

Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 169

PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 170

Ligand Pharma Enters Into Licencing Agreement With Merck 171

Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 172

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 173

Sigma Life Science Enters Into Licensing Agreement With Kyoto University 174

Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 175

Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 177

WntResearch Enters into Licensing Agreement with EMD Millipore 179

Affectis Pharma Enters Into Licensing Agreement With Merck Serono 180

Sigma Life Science Enters Into Licensing Agreement With King's College London 182

Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 183

Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 185

Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 186

Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin 188

Recordati Enters Into Licensing Agreement With Merck For Cardicor 189

Sanofi-aventis Enters Into Licensing Agreement With Merck Serono For AS703026 190

Merck Serono Enters Into Licensing Agreement With Sanofi-aventis For XL765 191

Plasticell Enters Into Licensing Agreement With Sigma-Aldrich 192

Millipore Enters into Licensing Agreement with Wayne State University 193

Allozyne Enters Into Licensing Agreement With Sigma-Aldrich 194

PregLem Enters Into Licensing Agreement With Merck Serono 195

University Of Illinois At Urbana-Champaign Enters Into Licensing Agreement With Sigma-Aldrich 196

EMD Millipore Enters Into Licensing Agreement With The Cleveland Clinic 197

Immunovaccine Enters Into License Agreement With Merck 198

Merck Serono Expands Licensing Agreement With Bionomics 199

Columbia Labs Renews Licensing Agreement With Merck Serono 200

Sigma-Aldrich Enters Into Licensing Agreement With CSIRO 201

Flexion Therapeutics Enters Into Licensing Agreement With Four Pharma Companies 202

Debt Offering 203

Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 203

Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 204

Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 205

Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 206

Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 207

Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 208

Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 209

Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 210

Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 211

Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 212

Sigma-Aldrich Completes An Underwritten Public Offering Of Senior Notes Due 2020 For US$300 Million 213

Asset Transactions 215

Merck May Sell Biosimilars Business 215

Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 216

Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 218

Eurofins Scientific To Acquire Assets Of Discovery And Development Solutions Business Of Merck 219

Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 221

Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 222

Noreva Pharma Acquires Dermo-Cosmetic Brands From Merck Medication 223

Acquisition 224

Merck Sells Bangalore Genei for USD1.5 Million 224

Merck Acquires Sigma-Aldrich for USD17 Billion 225

Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 228

Merck And BASF Acquire Majority Stake In Innovation Lab 229

Albany Molecular Research Completes Acquisition Of Cedarburg Pharma For US$41 Million 230

EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 232

Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 233

Proxy Labs Acquires MicroSafe Laboratories From Millipore 234

Sigma-Aldrich Completes Acquisition Of BioReliance For US$350 Million 235

Sigma-Aldrich Acquires Vetec Quimica Fina 237

Sigma-Aldrich Acquires Resource Technology 238

Teva Pharma Industries Acquires THERAMEX From Merck Serono 239

Merck Acquires Beijing Skywing Technology For US$18.2 Million 241

Sigma-Aldrich Acquires Cerilliant From Argenta Partners 242

Merck Completes Acquisition Of Millipore 244

Sigma-Aldrich Acquires Ace Animals 247

BioReliance Acquires CynerGene 248

Merck KGaA - Key Competitors 249

Key Employees 250

Locations And Subsidiaries 251

Head Office 251

Other Locations & Subsidiaries 251

Appendix 264

Methodology 264

About GlobalData 264

Contact Us 264

Disclaimer 264

List of Figures

Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 13

Merck KGaA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 15

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 16

Merck KGaA, Medical Devices Deals, 2010 to YTD 2016 18

List of Tables

Merck KGaA, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 13

Merck KGaA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 14

Merck KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 15

Merck KGaA, Deals By Therapy Area, 2010 to YTD 2016 16

Merck KGaA, Medical Devices Deals, 2010 to YTD 2016 18

Merck KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 19

Merck KgaA Acquires SevenSeas Original Brand 31

Merck Serono Acquires Worldwide Rights To PI-2301 From Peptimmune 32

Asceneuron Raises USD30.6 Million in Series A Financing 33

TocopheRx Raises US$3.3 Million In Seed Financing 35

Asceneuron Raises US$6.4 Million In Seed Financing 36

VAXIMM Secures US$8 Million In Venture Financing 37

Merck Sells Its Pharma Operations To Nkunzi Investment And Omame 39

Proteome Sciences Enters Into License Agreement With Sigma-Aldrich 40

BioMed X Enters into Agreement with Merck 41

Debiopharm Partners with Merck and Pfizer 42

Transgene Enters into Agreement with Merck and Pfizer 43

Vaccinex Enters into Agreement with Merck 44

PCAS Enters into Distribution Agreement with MilliporeSigma 45

MilliporeSigma Enters into Research Agreement with International Vaccine Institute 46

Selvita Enters into Agreement with Merck 47

Merck Enters into Agreement with University of Buea 48

Merck, Pfizer and Verastem Enter into Agreement 49

Merck Enters into Research Agreement with European Molecular Biology Labs 50

Merck, Pfizer and Syndax Pharma Enter into Agreement 51

Selvita Enters into Development and Commercialization Agreement with Merck 52

Biothera Pharma Enters into Partnership with Merck 53

Sigma-Aldrich Enters into Agreement with Sanger Institute 54

Sigma-Aldrich Enters into Distribution Agreement with IROA Technologies 55

Merck Serono Enters into Co-Development Agreement with Genea Biomedx and Illumina 56

Aeterna Zentaris Enters into Agreement with EMD Serono 57

Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 58

Lucigen Enters into Distribution Agreement with Sigma-Aldrich 59

Merck Serono Enters into Co-Development Agreement with MMV 60

Sigma-Aldrich Enters into Distribution Agreement with Roche 61

Merck Enters into Development Agreement with Precision Biologics 62

Indi Molecular Enters into Co-Development Agreement with Sigma-Aldrich 63

Pfizer Enters into Co-Development Agreement with Merck 64

BioSilta Enters into Co-Marketing Agreement with Sigma-Aldrich 66

Merck Serono Enters into Co-Development Agreement with Institute of Cancer Research and Wellcome Trust 67

Hutchison China MediTech Enters into Co-Promotion Agreement with Merck Serono for Cardiovascular Drug Products 68

Merck Plans to Enter into Co-Development Agreement for Anti-PD-L1 69

Lupin Enters into Co-Development Agreement with Merck Serono 70

Merck Serono Extends R&D Agreement with San Raffaele 71

Ventana Medical Systems Enters into Co-Development Agreement with Merck Serono for Companion Diagnostic Test 72

Merck Serono Enters into Co-Development Agreement with Sysmex Inostics 73

Bionovis Enters into Agreement with Merck 74

EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 75

EMD Millipore Enters Into Co-Development Agreement With Promethera Biosciences 77

KineMed Enters Into Agreement With EMD Serono To Identify Protein And Lipid Biomarkers 78

Biopharm Enters Into Research Agreement With Merck Serono 79

Merck Serono Enters Into Discovery Agreement With Lead Discovery Center 80

EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 81

Merck Serono Enters Into Co-Development Agreement With Selvita For Cancer Drugs 82

Merck Serono And Ablynx Extend Co-Discover And Development Agreement For Nanobodies 83

Sigma-Aldrich Enters Into Distribution Agreement With Paragon Scientific 85

Cancer Research Technology And Institute of Cancer Research Enter Into Agreement With Merck Serono For Drug Discovery 86

Gyros And EMD Millipore Enter Into Agreement To Develop And Commercialize Immunoassay Kits 88

Isu Abxis Enters into Co-Development Agreement with Merck 89

Luminex Extends Distribution Agreement With EMD Millipore 90

Merck Serono Enters Into Clinical Development Agreement With Quintiles Transnational 91

Sigma Life Science Enters Into Distribution Agreement With The Culture Collections of Public Health England 92

Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 93

Merck Enters Into Co-Development Agreement With Nordic Bioscience For Sprifermin 94

Merck Serono Enters Into Co-Development Agreement With Feinstein Institute For Therapy Of Inflammatory Diseases 96

EMD Millipore Enters Into Co-Development Agreement With Sistemic For Stem Cell Markers 97

AB Sciex Enters Into Distribution Agreement With Sigma-Aldrich For Sciex Ichemistry Solutions 98

EMD Millipore Enters Into Co-Marketing Agreement With Julphar Diabetes For Recombinant Human Insulin 99

Sigma Life Science Expands Agreement With Autism Speaks To Develop Rat Models For Autism Research 100

Sigma Life Science Enters Into Co-Marketing Agreement With Axiogenesis 101

Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 102

TI Pharma, Astellas Pharma And Merck Enter Into Co-Development Agreement With Swiss Tropical and Public Health 103

Genovis Enters Into Distribution Agreement With Sigma-Aldrich 104

Dr. Reddy's Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 105

EMD Millipore Enters Into Distribution Agreement With Ventria Bioscience 106

EMD Millipore Enters Into Co-Development Agreement With Centre for Commercialization of Regenerative Medicine 107

Merck Serono Enters Into Co-Development Agreement With Threshold Pharma For TH-302, Cancer Drug 108

Mapi Pharma Amends Co-Development Agreement with Merck 110

TriLink BioTechnologies Enters Into Distribution Agreement With Sigma-Aldrich 111

Ablynx Enters Into Third Co-Discovery And Co-Development Agreement With Merck Serono 112

IntelliCell BioSciences Enters Into Co-Marketing Agreement With Millipore 113

f-star Biotechnologische Enters Into Co-Development Agreement With Merck Serono 114

BASF Enters Into Distribution Agreement With Sigma-Aldrich 115

Lead Discovery Center Enters Into Agreement With Merck Serono 116

Merck Serono Enters Into Research Agreement With Philochem 117

Merck Serono Enters Into Co-Development Agreement With Sanofi-aventis 118

EMD Serono Enters Into Co-Marketing Agreement With Tercica 119

Merck Serono Extends Co-Development Agreement With INSpe And Department Of Neurology Of San Raffaele 120

Evotec Enters Into Collaboration With Merck KGaA 121

Domainex Enters Into Collaboration With Sigma-Aldrich 122

Sigma Life Science Enters Into Co-Marketing Agreement With JAX 123

Sigma Life Science Enters Into An Agreement With Autism Speaks 124

Ablynx Enters Into Second Co-Discovery And Co-Development Agreement With Merck Serono 125

EDELRIS Enters Into Collaboration With Merck Serono 126

Generex Biotech Enters Into Co-Marketing Agreement With Merck 127

Sigma Life Science Enters Into An Agreement With SwitchGear 128

Millipore Enters Into Collaboration With BioOutsource 129

Sigma-Aldrich Enters Into Distribution Agreement With New Mexico Highlands 130

Sigma-Aldrich Enters Into Distribution Agreement With Boehringer Ingelheim 131

Swedish Orphan Biovitrum Expands Distribution Agreement With Merck Serono 132

Eden Biodesign Enters Into A Collaboration With Millipore 133

Sigma-Aldrich Enters Into Commercialization Agreement With Pfizer 134

Sigma-Aldrich Enters Into Distribution Agreement With Eka Chemicals 135

BioCryst Pharma Enters Into Co-Marketing Agreement With Merck Serono 136

Cancer Research And Cancer Research Technology Enter Into An Agreement With Merck 137

Merck Enters into Licensing Agreement with Weizmann Institute of Science 138

Relief Therapeutics Enters into Licensing Agreement with Merck Serono 139

EMD Millipore Enters into Licensing Agreement with Singulex 140

Qualyst Transporter Solutions Enters into Licensing Agreement with BioReliance 141

Intrexon Enters into Licensing Agreement with Merck Serono 142

Sigma Life Science Enters into Licensing Agreement with Broad Institute for Crispr Gene Engineering System 143

EMD Serono Enters into Licensing Agreement with Sutro Biopharma 144

Allergopharma Enters into Licensing Agreement with S-TARget therapeutics 146

EMD Serono Enters into Licensing Agreement with Mersana Therapeutics 148

MorphoSys Enters into Licensing Agreement with Merck Serono 149

Merck Enters Into Licensing Agreement With Spanish National Cancer Research Centre 150

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 152

Sage Labs Enters Into Licensing Agreement With Caribou Biosciences 153

Sigma-Aldrich Enters Into Licensing Agreement With Horizon Discovery For CompoZr Zinc Finger Nuclease Technology 154

ObsEva Enters Into Licensing Agreement With Merck Serono 155

Cancer Research Technology, Cardiff University, And Institute of Cancer Research Extend Licensing Agreement With Merck Serono 156

Sigma-Aldrich Enters Into Licensing Agreement With Scripps Research Institute For Research Reagents 158

Cellular Dynamics Enters Into Licensing Agreement With Life Technologies And Sigma-Aldrich 160

Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 161

Merck Serono Amends its Licensing Agreement with BeiGene for BeiGene-283 162

Columbia Labs Extends Licensing Agreement With Merck Serono For Crinone 163

Merck Serono Amends Option and Licensing Agreement with Opexa Therapeutics 164

Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 166

EMD Millipore Enters Into Licensing Agreement With iPS Academia For Stem Cell Patents 167

Materia Extends Licensing Agreement With Sigma Aldrich 168

Plasticell Enters Into Licensing Agreement With EMD Millipore For Xeno-Free Osteogenic Medium 169

PDS Biotechnology Enters Into Licensing Agreement With Merck For Versamune 170

Ligand Pharma Enters Into Licencing Agreement With Merck 171

Sigma-Aldrich Enters Into Licensing Agreement With University of Illinois 172

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 173

Sigma Life Science Enters Into Licensing Agreement With Kyoto University 174

Merck Serono Enters Into Licensing Agreement With Ono Pharma For ONO-4641 175

Merck Serono Enters Into Licensing Agreement With Ono Pharma For Stimuvax 177

WntResearch Enters into Licensing Agreement with EMD Millipore 179

Affectis Pharma Enters Into Licensing Agreement With Merck Serono 180

Sigma Life Science Enters Into Licensing Agreement With King's College London 182

Newron Expands Licensing Agreement With Merck Serono For Pruvanserin And Sarizotan 183

Apeiron Biologics Enters Into Licensing Agreement With Merck For Hu14.18-IL2 185

Domain Therapeutics Enters Into Licensing Agreement With Merck Serono 186

Recordati Enters Into Licensing Agreement With Merck Serono For Pitavastatin 188

Recordati Enters Into Licensing Agreement With Merck For Cardicor 189

Sanofi-aventis Enters Into Licensing Agreement With Merck Serono For AS703026 190

Merck Serono Enters Into Licensing Agreement With Sanofi-aventis For XL765 191

Plasticell Enters Into Licensing Agreement With Sigma-Aldrich 192

Millipore Enters into Licensing Agreement with Wayne State University 193

Allozyne Enters Into Licensing Agreement With Sigma-Aldrich 194

PregLem Enters Into Licensing Agreement With Merck Serono 195

University Of Illinois At Urbana-Champaign Enters Into Licensing Agreement With Sigma-Aldrich 196

EMD Millipore Enters Into Licensing Agreement With The Cleveland Clinic 197

Immunovaccine Enters Into License Agreement With Merck 198

Merck Serono Expands Licensing Agreement With Bionomics 199

Columbia Labs Renews Licensing Agreement With Merck Serono 200

Sigma-Aldrich Enters Into Licensing Agreement With CSIRO 201

Flexion Therapeutics Enters Into Licensing Agreement With Four Pharma Companies 202

Merck Raises USD801.4 Million in Private Placement of 0.23% Bonds Due 2017 203

Merck Raises USD916 Million in Private Placement of 0.75% Bonds Due 2019 204

Merck Raises USD629.7 Million in Private Placement of 1.375% Bonds Due 2022 205

Merck Raises USD1 Billion in Private Placement of 2.95% Notes Due 2022 206

Merck Raises USD400 Million in Private Placement of 1.7% Notes Due 2018 207

Merck Raises USD750 Million in Private Placement of 2.4% Notes Due 2020 208

Merck Raises USD250 Million in Private Placement of Floating Rate Notes Due 2017 209

Merck Raises USD1.6 Billion in Private Placement of 3.25% Notes Due 2025 210

Merck Raises USD1.2 Billion in Private Placement of 2.625% Bonds Due 2074 211

Merck Raises USD614 Million in Private Placement of 3.375% Bonds Due 2074 212

Sigma-Aldrich Completes An Underwritten Public Offering Of Senior Notes Due 2020 For US$300 Million 213

Merck May Sell Biosimilars Business 215

Honeywell International Acquires Research Chemicals Business from Sigma-Aldrich 216

Schussler Novachem to Acquire Lab Equipment and Production Units from Merck 218

Eurofins Scientific To Acquire Assets Of Discovery And Development Solutions Business Of Merck 219

Kaneq Pharma Acquires Intellectual Property for PTP-1B Insulin-Sensitizer Program from Merck 221

Corpak MedSystems Acquires Gastroenterology Sales And Distribution Operations Of Merck Serono 222

Noreva Pharma Acquires Dermo-Cosmetic Brands From Merck Medication 223

Merck Sells Bangalore Genei for USD1.5 Million 224

Merck Acquires Sigma-Aldrich for USD17 Billion 225

Johnson Matthey Acquires SAFC Pharmorphix from Sigma-Aldrich 228

Merck And BASF Acquire Majority Stake In Innovation Lab 229

Albany Molecular Research Completes Acquisition Of Cedarburg Pharma For US$41 Million 230

EMD Millipore Completes Acquisition Of Biochrom, Provider Of Cell Culture Media Products 232

Sigma-Aldrich Acquires Research Organics, Manufacturer Of Biochemicals 233

Proxy Labs Acquires MicroSafe Laboratories From Millipore 234

Sigma-Aldrich Completes Acquisition Of BioReliance For US$350 Million 235

Sigma-Aldrich Acquires Vetec Quimica Fina 237

Sigma-Aldrich Acquires Resource Technology 238

Teva Pharma Industries Acquires THERAMEX From Merck Serono 239

Merck Acquires Beijing Skywing Technology For US$18.2 Million 241

Sigma-Aldrich Acquires Cerilliant From Argenta Partners 242

Merck Completes Acquisition Of Millipore 244

Sigma-Aldrich Acquires Ace Animals 247

BioReliance Acquires CynerGene 248

Merck KGaA, Key Competitors 249

Merck KGaA, Key Employees 250

Merck KGaA, Subsidiaries 251

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Merck KGaA , Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com